A Phase I/IB Randomized, Double-blind, Placebo Controlled, Dose-finding Study to Evaluate Safety, Tolerability of TG1050 Single/Multiple Doses, and Evaluation of TG1050 Immunologic/Antiviral Activity in Patients With Chronic Hep B Infection

Trial Profile

A Phase I/IB Randomized, Double-blind, Placebo Controlled, Dose-finding Study to Evaluate Safety, Tolerability of TG1050 Single/Multiple Doses, and Evaluation of TG1050 Immunologic/Antiviral Activity in Patients With Chronic Hep B Infection

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 17 Oct 2017

At a glance

  • Drugs TG 1050 (Primary)
  • Indications Hepatitis B
  • Focus Adverse reactions; First in man
  • Sponsors Transgene
  • Most Recent Events

    • 17 Oct 2017 Status changed from recruiting to active, no longer recruiting, according to a Transgene media release.
    • 13 Sep 2017 According to a Transgene media release, results from the first part of the study will be presented at the American Association for the Study of Liver Diseases (AASLD) meeting (Oct 2017).
    • 17 Oct 2016 According to Transgene media release, First Patient Randomized in Multiple Dose Cohort and first data readout is expected in second half of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top